Navigation Links
H5N1 avian flu virus vaccine induces immune responses in healthy adults

greater the antibody response produced. Of the 99 people evaluated in the 90-mcg, high-dose group, 54 percent achieved a neutralizing antibody response to the vaccine at serum dilutions of 1:40 or greater, whereas only 22 percent of the 100 people evaluated who received the 15-mcg dose developed a similar response to the vaccine.

Generally, all dosages of the vaccine appeared to be well tolerated:

  • Almost all reported side effects were mild
  • The second dose of vaccine did not cause more local or systemic symptoms than the first
  • Systemic complaints of fever, malaise, muscle aches, headaches and nausea occurred with the same frequency in all dosage groups as in the placebo group
  • Lab tests did not reveal any clinically significant abnormalities

The vaccine, made from an inactivated H5N1 virus isolated in Southeast Asia in 2004, was manufactured by sanofi pasteur, Swiftwater, PA, under contract to NIAID. Because there are no manufacturers licensed in the United States to use adjuvants in inactivated influenza vaccines, NIAID's first step was to test an H5N1 influenza vaccine made in a way that mimics the process used to make conventional flu vaccines. The clinical data collected in this study are now available to support the potential use of this vaccine should it be needed for an emerging pandemic.


'"/>

Source:NIH/National Institute of Allergy and Infectious Diseases


Page: 1 2 3

Related biology news :

1. Bird samples from Mongolia confirmed as H5N1 avian flu
2. WCS says avian flu prevention should focus on farms, markets
3. Less virulent strains of avian influenza can infect humans
4. Drug resistant avian influenza viruses more common in Southeast Asia than North America
5. Volunteers sought for avian flu vaccine study
6. Vaccine provides 100 percent protection against avian flu virus in animal study
7. Medical experts: US unlikely to have enough vaccines to stop avian flu
8. Minor mutations in avian flu virus increase chances of human infection
9. H9N2 avian flu vaccine paired with adjuvant provokes strong human immune response at low doses
10. Pacific Rim researchers to collaborate on distributed bioinformatics analysis of avian flu
11. Map predicting spread of avian flu
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: avian flu virus vaccine induces immune responses healthy adults

(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... 7, 2008 -- Oncolytics Biotech Inc. (TSX: ONC, ... group led by Dr. Richard Vile of the ... published the results of its work testing the ... reovirus and cyclophosphamide in vivo. The paper, ...
... of Massachusetts Medical School and the Carnegie Institution of ... agreements with Oxford BioMedica (LSE: OXB), a gene ... RNA interference (RNAi) patent rights. The ... Fire, PhD, and Craig C. Mello, PhD, and their ...
... variation and evolution of reproductive systems of flowering plants ... sciences. In a special issue of the International ... the University of Toronto gathers together in a single ... three areas that have seen the most growth: flowers ...
Cached Biology News:U. Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica 2A special issue of the International Journal of Plant Sciences 2A special issue of the International Journal of Plant Sciences 3
(Date:7/29/2015)... ... 2015 , ... Nearly everyone has heard of the potential of stem cells ... rich source of these cells is teeth—baby teeth that come loose during childhood, wisdom ... to make room for braces. These potent stem cells exist in the dental ...
(Date:7/28/2015)... , July 28, 2015  PDL BioPharma, Inc. ... announced that the Company will release its second quarter ... 2015, on Wednesday, August 5, 2015, after market close. ... that day at 4:30 p.m. Eastern Time to discuss ... call will be available via the webcast link on ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... ) has announced the addition of the ... report to their offering. Globally, ... applications including immuno-phenotyping, cell proliferation, cancer, and stem ... in clinical applications primarily because of demand from ...
(Date:7/28/2015)... Tauriga Sciences, Inc. (OTCQB:  TAUG) or ("Tauriga" ... announced that its stockholders approved an increase in the ... Company from 1,000,000,000 to 2,500,000,000 at its Special Meeting ... Law Offices of Nixon Peabody LLP in Midtown Manhattan ... 480,655,929 shares of common stock represented either by proxy ...
Breaking Biology Technology:Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3
... SAN MARINO, Calif., Feb. 12 Epeius Biotechnologies ... containing an award-winning video and an interactive e-book ... tumor-targeting and cancer-destroying biotechnologies behind the clinical development ... so far only targeted, genetic medicine that has ...
... GuidanceCompany Reiterates 2009 Earnings Guidance and Introduces Q1 2009 ... Cephalon, Inc . (Nasdaq: CEPH ) today ... of $1.727 billion for 2007, exceeding the company,s previously ... the full year 2008 was $3.27. Excluding amortization ...
... coverage to include GPCR directed screening and drug ... Inc. announced today that it has been granted ... for G-Protein-Coupled Receptors and their Signaling Pathways." ... and for identifying drug leads based on their ...
Cached Biology Technology:Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial 2Cephalon's New Product Launches Pace Record 2008 Sales 2Cephalon's New Product Launches Pace Record 2008 Sales 3Cephalon's New Product Launches Pace Record 2008 Sales 4Cephalon's New Product Launches Pace Record 2008 Sales 5Cephalon's New Product Launches Pace Record 2008 Sales 6Cephalon's New Product Launches Pace Record 2008 Sales 7Cephalon's New Product Launches Pace Record 2008 Sales 8Cephalon's New Product Launches Pace Record 2008 Sales 9Cephalon's New Product Launches Pace Record 2008 Sales 10Cephalon's New Product Launches Pace Record 2008 Sales 11Cephalon's New Product Launches Pace Record 2008 Sales 12Cephalon's New Product Launches Pace Record 2008 Sales 13Cephalon's New Product Launches Pace Record 2008 Sales 14Cephalon's New Product Launches Pace Record 2008 Sales 15Cephalon's New Product Launches Pace Record 2008 Sales 16Cephalon's New Product Launches Pace Record 2008 Sales 17Cephalon's New Product Launches Pace Record 2008 Sales 18Cephalon's New Product Launches Pace Record 2008 Sales 19Cephalon's New Product Launches Pace Record 2008 Sales 20Cephalon's New Product Launches Pace Record 2008 Sales 21Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy 2
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Biology Products: